MCID: SCR003
MIFTS: 36

Secretory Diarrhea malady

Categories: Gastrointestinal diseases

Aliases & Classifications for Secretory Diarrhea

Aliases & Descriptions for Secretory Diarrhea:

Name: Secretory Diarrhea 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050129

Summaries for Secretory Diarrhea

Disease Ontology : 12 Secretory diarrhea is a diarrhea where there is an increase in the active secretion, or there is an inhibition of absorption causing little to no structural damage. The most common cause of this type of diarrhea is a cholera toxin that stimulates the secretion of anions, especially chloride ions.

MalaCards based summary : Secretory Diarrhea is related to secretory diarrhea myopathy and deafness and immunodysregulation, polyendocrinopathy, and enteropathy, x-linked, and has symptoms including diarrhea and intermittent diarrhea. An important gene associated with Secretory Diarrhea is CFTR (Cystic Fibrosis Transmembrane Conductance Regulator), and among its related pathways/superpathways are Mineral absorption and CFTR-dependent regulation of ion channels in Airway Epithelium (norm and CF). The drugs Omeprazole and Ondansetron have been mentioned in the context of this disorder. Affiliated tissues include colon, bone and skin, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Related Diseases for Secretory Diarrhea

Diseases related to Secretory Diarrhea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 71)
id Related Disease Score Top Affiliating Genes
1 secretory diarrhea myopathy and deafness 12.0
2 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.6
3 diarrhea 3, secretory sodium, congenital, syndromic 11.6
4 immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome 11.3
5 villous adenoma 11.2
6 congenital chloride diarrhea 11.1
7 congenital secretory sodium diarrhea 8 11.1
8 ipex syndrome 11.0
9 diarrhea 1, secretory chloride, congenital 10.9
10 diarrhea 10.6
11 hyperferritinemia-cataract syndrome 10.2 SLC9A3 SPINT2
12 colorectal cancer, hereditary nonpolyposis, type 8 10.2 MYO5B SPINT2
13 short bowel syndrome 10.2 CFTR SST
14 wells-jankovic syndrome 10.1 SST VIP
15 choline deficiency disease 10.1 SST VIP
16 gmppa-cdg 10.1 SST VIP
17 volkmann contracture 10.1 SST VIP
18 spinal stenosis 10.1 SST VIP
19 gemistocytic astrocytoma 10.1 SST VIP
20 drug psychosis 10.1 SST VIP
21 eec syndrome 10.1 MYO5B SLC9A3 SPINT2
22 acute pyelonephritis 10.1 SST VIP
23 maturity-onset diabetes of the young, type 13 10.1 SST VIP
24 glomerulosclerosis, focal segmental, 1 10.1 MYO5B SLC9A3
25 bone dysplasia azouz type 10.1 SST VIP
26 myopathy, lactic acidosis, and sideroblastic anemia 2 10.1 CFTR GUCY2C SLC9A3
27 cholera 10.1
28 keloids 10.1 SST VIP
29 pertussis 10.0 CFTR XK
30 photoparoxysmal response 3 10.0 SST XK
31 squamous blepharitis 10.0 CFTR XK
32 spinal meningioma 10.0 FOXP3 VIP
33 myoepithelial carcinoma 10.0 SST VIP
34 ariboflavinosis 9.9 CFTR GUCY2C
35 adenoma 9.9
36 mednik syndrome 9.9 SLC26A3 SLC9A3 XK
37 superficial mycosis 9.8 SLC26A3 SLC9A3 XK
38 hyperlysinemia 9.8 CFTR GUCY2C SLC9A3 VIP
39 crohn's disease 9.8
40 colitis 9.8
41 collagenous colitis 9.6
42 myopathy 9.6
43 jejunoileitis 9.6
44 pancreatitis 9.6
45 pneumonia 9.6
46 congenital myopathy 9.6
47 connective tissue disease 9.6
48 protein-losing enteropathy 9.6
49 cystic fibrosis 9.6
50 giardiasis 9.6

Graphical network of the top 20 diseases related to Secretory Diarrhea:



Diseases related to Secretory Diarrhea

Symptoms & Phenotypes for Secretory Diarrhea

UMLS symptoms related to Secretory Diarrhea:


diarrhea, intermittent diarrhea

MGI Mouse Phenotypes related to Secretory Diarrhea:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 CFTR FOXP3 GUCY2C MYO5B SLC26A3 SLC9A3
2 homeostasis/metabolism MP:0005376 9.61 FOXP3 GUCY2C MYO5B SLC26A3 SLC9A3 SST
3 mortality/aging MP:0010768 9.23 CFTR FOXP3 GUCY2C MYO5B SLC26A3 SPINT2

Drugs & Therapeutics for Secretory Diarrhea

Drugs for Secretory Diarrhea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
2
Ondansetron Approved Phase 4 99614-02-5 4595
3
Somatostatin Approved Phase 4,Phase 3,Phase 1,Phase 2 38916-34-6, 51110-01-1 53481605
4 Pinaverium Approved Phase 4 59995-65-2
5
lanreotide Approved Phase 4,Phase 3 108736-35-2
6
Glyburide Approved Phase 4 10238-21-8 3488
7 Anti-Anxiety Agents Phase 4
8 Antiemetics Phase 4
9 Antipruritics Phase 4
10 Antipsychotic Agents Phase 4
11 Autonomic Agents Phase 4
12 Central Nervous System Depressants Phase 4,Phase 2
13 Dermatologic Agents Phase 4
14 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Neurotransmitter Agents Phase 4
16 Peripheral Nervous System Agents Phase 4,Phase 2
17 Psychotropic Drugs Phase 4
18
Serotonin Phase 4 50-67-9 5202
19 Serotonin Agents Phase 4
20 Serotonin Antagonists Phase 4
21 Tranquilizing Agents Phase 4
22 Analgesics Phase 4,Phase 2
23 Analgesics, Non-Narcotic Phase 4
24 Anti-Inflammatory Agents Phase 4,Phase 2
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4
26 Antirheumatic Agents Phase 4
27 Mesalamine Phase 4 89-57-6
28 Glucagon-Like Peptide 1 Phase 4,Phase 3
29 Hypoglycemic Agents Phase 4,Phase 3,Phase 1,Phase 2
30 insulin Phase 4,Phase 3,Phase 1,Phase 2
31 Insulin, Globin Zinc Phase 4,Phase 3,Phase 1,Phase 2
32 Anticonvulsants Phase 4
33 Bromides Phase 4
34 calcium channel blockers Phase 4
35 Calcium, Dietary Phase 4
36 Parasympatholytics Phase 4
37 Angiopeptin Phase 4,Phase 3
38 Hormone Antagonists Phase 4,Phase 3,Phase 2
39 Hormones Phase 4,Phase 3,Phase 2
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
41 glucagon Phase 4
42
Zinc Approved Phase 2, Phase 3 7440-66-6 32051 23994
43
Insulin Glargine Approved Phase 3 160337-95-1
44
Menthol Approved Phase 3 2216-51-5 16666
45
Loperamide Approved Phase 3,Phase 2 53179-11-6 3955
46 Pharmaceutical Solutions Phase 2, Phase 3,Phase 1
47 Antidiarrheals Phase 3,Phase 2
48 Acidophilus Nutraceutical Phase 3
49
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
50
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441

Interventional clinical trials:

(show all 41)
id Name Status NCT ID Phase
1 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
2 Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D) Completed NCT00745004 Phase 4
3 Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D) Completed NCT01316718 Phase 4
4 Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction Recruiting NCT02833103 Phase 4
5 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Active, not recruiting NCT02075606 Phase 4
6 Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes Enrolling by invitation NCT02624817 Phase 4
7 Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR) Enrolling by invitation NCT02624830 Phase 4
8 A Pilot Study of Filtrum-STI in Children With Viral Gastroenteritis Unknown status NCT01113346 Phase 2, Phase 3
9 Oral Rehydration Solution With Zinc and Prebiotics in Acute Diarrhea Completed NCT01025583 Phase 2, Phase 3
10 Fermented Milk and Fermented Rice on the Appearance of Respiratory and Gastrointestinal Symptoms Completed NCT01909128 Phase 3
11 Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin Completed NCT02168491 Phase 3
12 Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study Recruiting NCT02354768 Phase 3
13 Probiotics in Irritable Bowel Syndrome Withdrawn NCT00846170 Phase 3
14 Isoleucine Added ORS in Children With Diarrhoea Completed NCT01034228 Phase 2
15 Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Completed NCT00672308 Phase 2
16 Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT00780663 Phase 2
17 Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain Completed NCT01275755 Phase 2
18 Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain Completed NCT01207427 Phase 2
19 Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine Completed NCT00210288 Phase 2
20 Glucose Clamp Study to Prove Hypo- and Hyperglycemic Episodes Using a Non-invasive Glucose Monitoring Device Completed NCT01060917 Phase 1, Phase 2
21 Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy Recruiting NCT03094052 Phase 2
22 Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh Recruiting NCT02531802 Phase 1, Phase 2
23 Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors Recruiting NCT01782443 Phase 2
24 Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel Terminated NCT01469338 Phase 2
25 Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa Terminated NCT00866476 Phase 2
26 Efficacy of iOWH032 in Dehydrating Cholera Withdrawn NCT02111304 Phase 2
27 Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection Completed NCT01129453 Phase 1
28 Phase I Study of ETEC Vaccine Completed NCT01147445 Phase 1
29 A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver Recruiting NCT02693067 Phase 1
30 Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea Recruiting NCT02067676 Phase 1
31 Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus Not yet recruiting NCT02950688 Phase 1
32 Enteroaggregative E.Coli (EAEC) Terminated NCT00362869 Phase 1
33 Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 Completed NCT01406288
34 Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation Completed NCT01162863
35 Idiopathic Reactive Hypoglycaemia and Treatment With Fructo-Oligosaccharide Completed NCT00802971
36 Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD Completed NCT02197780
37 Probiotics Against Pathogenic Bacteria in Advanced ENT-Surgery Recruiting NCT01730066
38 Effect of Different Concentrations of Xylitol and Erythritol on Gut Peptide Release and Gastric Emptying in Humans Recruiting NCT03039478
39 Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D Active, not recruiting NCT02163213
40 Treatment of Latent Autoimmune Diabetes of the Adult Active, not recruiting NCT01140438
41 Parasitic Causes of Secretory Diarrhea in Children and Chronically Ill Adult. Not yet recruiting NCT03166670

Search NIH Clinical Center for Secretory Diarrhea

Genetic Tests for Secretory Diarrhea

Anatomical Context for Secretory Diarrhea

MalaCards organs/tissues related to Secretory Diarrhea:

39
Colon, Bone, Skin, Bone Marrow, Small Intestine

Publications for Secretory Diarrhea

Articles related to Secretory Diarrhea:

(show top 50) (show all 84)
id Title Authors Year
1
Pharmacologic Comparison of Clinical Neutral Endopeptidase Inhibitors in a Rat Model of Acute Secretory Diarrhea. ( 26907621 )
2016
2
A case report of a giant rectal adenoma causing secretory diarrhea and acute renal failure: McKittrick-Wheelock syndrome. ( 27267899 )
2016
3
Pathogen-induced secretory diarrhea and its prevention. ( 27473379 )
2016
4
Gut microbial succession follows acute secretory diarrhea in humans. ( 25991682 )
2015
5
Drug-induced secretory diarrhea: A role for CFTR. ( 26429773 )
2015
6
Crofelemer: In Hiv Associated Diarrhea and Secretory Diarrhea- A Patent Perspective. ( 25851117 )
2015
7
Crofelemer for the treatment of secretory diarrhea. ( 22149578 )
2012
8
Crofelemer, a novel agent for treatment of secretory diarrhea. ( 20388859 )
2010
9
Intractable secretory diarrhea in a Japanese boy with mitochondrial respiratory chain complex I deficiency. ( 18560889 )
2009
10
Oral delivery of L-arginine stimulates prostaglandin-dependent secretory diarrhea in Cryptosporidium parvum-infected neonatal piglets. ( 18223372 )
2008
11
We may be able to stop common lethal secretory diarrhea by activating the intestinal calcium sensing receptors. ( 17435618 )
2007
12
Preventive effects of the probiotic Escherichia coli strain Nissle 1917 on acute secretory diarrhea in a pig model of intestinal infection. ( 16614995 )
2006
13
Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions. ( 16203867 )
2005
14
Stimulated active potassium secretion in a patient with colonic pseudo-obstruction: a new mechanism of secretory diarrhea. ( 16230079 )
2005
15
Legionella micdadei infection presenting as severe secretory diarrhea and a solitary pulmonary mass. ( 15034849 )
2004
16
Ataxia and secretory diarrhea: two unusual paraneoplastic syndromes occurring concurrently in the same patient with ganglioneuroblastoma. ( 15342979 )
2004
17
Secretory diarrhea owing to a tape bezoar in a child with Hirschsprung's disease. ( 14614723 )
2003
18
Congenital myopathy, recurrent secretory diarrhea, bullous eruption of skin, microcephaly, and deafness: a new genetic syndrome? ( 12476446 )
2003
19
Alternative treatment for secretory diarrhea revealed in a new class of CFTR inhibitors. ( 12464662 )
2002
20
Role of the enteric nervous system in the pathophysiology of secretory diarrhea. ( 12041649 )
2002
21
Effects of an alanyl-glutamine-based oral rehydration and nutrition therapy solution on electrolyte and water absorption in a rat model of secretory diarrhea induced by cholera toxin. ( 12044816 )
2002
22
Acute appendicitis presenting as secretory diarrhea. ( 12037768 )
2002
23
Continuous octreotide infusion for the treatment of secretory diarrhea caused by acute intestinal graft-versus-host disease in a child. ( 10959906 )
2000
24
New insights into the pathogenesis of intestinal dysfunction: secretory diarrhea and cystic fibrosis. ( 11830825 )
2000
25
Adenocarcinoma of the colon with neuroendocrine features and secretory diarrhea. ( 10364049 )
1999
26
Secretory diarrhea. ( 10980977 )
1999
27
Lansoprazole: a cause of secretory diarrhea. ( 9820425 )
1998
28
Efficacy of a glutamine-based oral rehydration solution on the electrolyte and water absorption in a rabbit model of secretory diarrhea induced by cholera toxin. ( 9586761 )
1998
29
Effects of KW-5617 (zaldaride maleate), a potent and selective calmodulin inhibitor, on secretory diarrhea and on gastrointestinal propulsion in rats. ( 9541283 )
1998
30
Effect of fludrocortisone and spironolactone on sodium and potassium losses in secretory diarrhea. ( 9009126 )
1997
31
Secretory diarrhea caused by ipecac poisoning. ( 9161961 )
1997
32
Secretory diarrhea in children: newly recognized toxins and hormone-secreting tumors. ( 8614604 )
1996
33
Massive secretory diarrhea and pseudo-obstruction as the initial presentation of Crohn's disease. ( 8835903 )
1996
34
Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. ( 7628270 )
1995
35
Human intestinal cryptosporidiosis: secretory diarrhea and enterotoxic activity in Caco-2 cells. ( 7706827 )
1995
36
Hexamethonium and secretory diarrhea. ( 7797038 )
1995
37
A pharmacological approach to secretory diarrhea. ( 7743122 )
1995
38
Reactive oxygen and nitrogen metabolites as mediators of secretory diarrhea. ( 7498670 )
1995
39
Effect of psyllium, calcium polycarbophil, and wheat bran on secretory diarrhea induced by phenolphthalein. ( 8385040 )
1993
40
Bicarbonate and citrate in oral rehydration therapy: studies in a model of secretory diarrhea. ( 8492256 )
1993
41
Control study of oral rehydration solution (ORS)/ORS + dioctahedral smectite in hospitalized Thai infants with acute secretory diarrhea. ( 1488694 )
1992
42
Sigmoid volvulus presenting as chronic secretory diarrhea responsive to octreotide. ( 1728114 )
1992
43
The effect of nifedipine on secretory diarrhea in mice. ( 1440948 )
1992
44
Secretory diarrhea in villous adenoma of rectum: effect of treatment with somatostatin and indomethacin. ( 1410521 )
1992
45
Secretory diarrhea and candidal overgrowth: cause and effect? ( 1894948 )
1991
46
Congenital diabetes mellitus and fatal secretory diarrhea in two infants. ( 1779317 )
1991
47
Secretory diarrhea following a dog bite. ( 1864208 )
1991
48
Alanine stimulation of water and sodium absorption in a model of secretory diarrhea. ( 2303972 )
1990
49
Severe secretory diarrhea with elevated gastrin-releasing peptide controlled by somatostatin analogue: a case report. ( 1980089 )
1990
50
The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. ( 2360261 )
1990

Variations for Secretory Diarrhea

Expression for Secretory Diarrhea

Search GEO for disease gene expression data for Secretory Diarrhea.

Pathways for Secretory Diarrhea

Pathways related to Secretory Diarrhea according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.66 SLC26A3 SLC9A3
2 10.17 CFTR SPINT2

GO Terms for Secretory Diarrhea

Cellular components related to Secretory Diarrhea according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.13 CFTR SLC26A3 SLC9A3
2 brush border membrane GO:0031526 8.62 SLC26A3 SLC9A3

Biological processes related to Secretory Diarrhea according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cellular response to cAMP GO:0071320 9.37 CFTR SLC26A3
2 bicarbonate transport GO:0015701 9.32 CFTR SLC26A3
3 regulation of intracellular pH GO:0051453 9.26 SLC26A3 SLC9A3
4 sperm capacitation GO:0048240 9.16 CFTR SLC26A3
5 membrane hyperpolarization GO:0060081 8.96 CFTR SLC26A3
6 intracellular pH elevation GO:0051454 8.62 CFTR SLC26A3

Molecular functions related to Secretory Diarrhea according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 antiporter activity GO:0015297 9.16 SLC26A3 SLC9A3
2 bicarbonate transmembrane transporter activity GO:0015106 8.96 CFTR SLC26A3
3 chloride transmembrane transporter activity GO:0015108 8.62 CFTR SLC26A3

Sources for Secretory Diarrhea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....